TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04419649: A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Sponsor: Takeda · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 210 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT04419649 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04419649 Rescue Dossier →